Literature
The G-Rex® Grant Program puts $20 million behind cell and gene modified cell therapy developers, awarding each recipient $5,000 to $300,000 of products through a partnership of ScaleReady, Wilson Wolf Manufacturing, Bio-Techne and CellReady. Awards cover G-Rex® M series bioreactors and the GatheRex pump, animal free, T cell and NK media, GMP cytokines including IL-2, IL-7, IL-15 and IL-21, and TcBuster, plus unlimited free consulting covering batch record review and optimisation, technical application support and guidance from former FDA and EMA CMC reviewers. Commercial and academic groups doing preclinical research, process development or cGMP manufacturing qualify. The flyer states G-R…
Literature
ScaleReady's G-Rex® Grant Program is a $20,000,000 initiative run with Wilson Wolf, Bio-Techne and CellReady that gives each recipient between $5,000 and $300,000 of materials and services plus free consulting from G-Rex® Optimization Specialists over a collaboration period of up to 18 months. Awards supply G-Rex® well plates and bioreactors including closed system models, the GatheRex Cell Harvest Pump, RUO and GMP reagents and media, the TcBuster transposon system, and process development support. Applicants must work on cell and gene modified cell therapies derived from T cells, NK cells or HSCs and be working towards an IND. Typical deliverables include IND-enabling or amendment data…
Videos
Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf , an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex® ® bioreactors.
Scientific Posters
T-Cells
G-Rex®500M, G-Rex®500M-TF
Closing the downstream steps of the AgonOx T-cell manufacturing process cut average processing time from five hours to three, roughly 40 per cent, while cell recovery held steady. Three engineering runs were finished inside a two-month window and measured against 23 historical manual runs. Viable cell recovery after processing was 81.2 per cent with the closed workflow and 82.3 per cent with the manual one, but run-to-run spread collapsed, standard deviation falling from 23.1 per cent to 0.033 per cent. The team swapped the previously validated open G-Rex®500M for a sterile-weldable G-Rex®500M-TF, added the GatheRex harvest pump and the Lovo washing system, and folded all three into a run…
Application Notes
CAR T Cells
Surface CAR density on CD19 CAR T cells halved within 30 minutes of meeting CD19-coated beads, sank to background by 60 minutes and vanished by four hours, followed through the Whitlow/218 linker by flow cytometry. Whole-cell lysate read on a capillary Western system showed the same loss starting earlier, at 10 minutes, bottoming at 60 minutes and then climbing again at four hours, which points to receptor recycling rather than destruction. ERK1/2 phosphorylation peaked at a two-fold rise 15 minutes after stimulation and then fell steadily. HER2-coated beads and CAR-negative cells produced no change. Primary T cells were transposed at 10 x 10^6 per sample and rested 11 days in IL-7 and IL…
Case Studies
CAR T Cells
G-Rex®100M
Seeding a G-Rex® 100M Series bioreactor with 50 million elutriated lymphocytes yielded 3 to 5 billion T cells while consuming just 1 L of medium. A CAR-T manufacturer facing supply-chain shortages of WAVE bioreactor culture bags tested peripheral blood in place of full apheresis units and ran G-Rex® closed-system bioreactors alongside the WAVE in parallel. Final products were compared on viability, transduction efficiency, phenotype and other critical quality attributes, and the G-Rex®-grown cells met the fold-expansion, transduction and dose specifications. Against the WAVE process, G-Rex® needed one quarter of the starting material, one fifth of the media volume and one third of the con…
Scientific Posters
CAR T Cells, NK Cells, T-Cells
A directed-evolution mutant of the TcBuster transposase, TcB-M, drove cargo integration above 60 per cent in primary T cells and peripheral blood NK cells without sacrificing cell growth or raising clonal dominance concerns. The mutant came out of a mammalian high-throughput screen of more than 3 million variants, a far larger library than those behind piggyBac or Sleeping Beauty. Head-to-head against both, using an EF1a-CD19-DHFR-eGFP transposon electroporated into CD4+CD8+ T cells and read on day 7 across at least three donors, TcB-M reached higher transposition with less transposon and gentler programs. It also integrated more randomly than lentivirus, and runs from vector map to GMP t…
Scientific Posters
CD34 Cells, NK Cells
Raising CD34-positive progenitor output during induced pluripotent stem cell differentiation lifted the final yield of induced NK cells roughly 24-fold over a published protocol while keeping purity above 95 per cent CD56-positive CD3-negative at day 28. Embryoid bodies showed an enriched CD34-positive population by day 11 with minimal CD45 and CD43 staining; by day 21 most cells were CD45-positive common lymphoid progenitors containing a small CD56-positive subset. Differentiated cells lost CD34 and variably expressed CD16, NKp46, NKp30 and NKG2D at levels comparable with peripheral blood NK cells. Replacing irradiated K562 feeders with an antibody cocktail during expansion preserved kil…
Protocols
NK Cells
This feeder-cell process expands enriched human NK cells in a G-Rex®6M well plate, seeding 5 x 10^4 to 5 x 10^5 NK cells per cm^2 together with gamma-irradiated feeder cells given 100 Gy, at a 1:2 NK-to-feeder ratio. ExCellerate Human NK Cell Expansion Medium is supplemented with 50 IU/mL IL-2, optionally with 2 to 5 per cent human AB serum, and a single well takes a maximum working volume of 100 mL. Cultures are left undisturbed for five days, then half the medium is replaced with medium at 100 IU/mL IL-2 so the working concentration returns to 50 IU/mL, repeated every three to four days, with weekly feeder restimulation at a 1:1 ratio.
Protocols
NK Cells
This feeder-free process expands enriched human NK cells in a G-Rex®6M well plate with no feeder line at all, seeding 2.5 x 10^6 NK cells per cm^2 in ExCellerate Human NK Cell Expansion Medium. The starting cytokine cocktail is 250 IU/mL IL-2 plus IL-12, IL-15, IL-18 and IL-21 each at 10 ng/mL, with optional human AB serum at 2 to 5 per cent, and one well holds a maximum working volume of 100 mL. Cells sit undisturbed for five days, after which half the medium is exchanged for medium containing 500 IU/mL IL-2 and 20 ng/mL each of IL-15, IL-18 and IL-21, dropping IL-12, and this is repeated every three to four days.
Literature
NK Cells
Purified human NK cells expanded roughly 1,078 to 3,009 fold over a 14-day culture in ExCellerate Human NK Cell Expansion Media, animal component-free, across four healthy donors. The process was serum-free and used irradiated feeder cells together with a cytokine cocktail of animal-free human IL-2 and IL-15. Expanded cells retained killing capacity and were profiled per donor for CD16 and NKG2D. A separate 11-marker panel on three further donors covered activating receptors, effector molecules including perforin and granzyme B, chemokine receptors and inhibitory KIRs, alongside high NK purity and several hundred fold expansion. Release specifications list endotoxin at or below 1.0 EU/mL…
Literature
T-Cells
Ready-to-use liquid frozen GMP IL-2, IL-7 and IL-15 matched their lyophilised counterparts in both bioactivity and T cell output. Dose-response proliferation assays run on CTLL-2 mouse cytotoxic T cells, PHA-activated human peripheral blood lymphocytes and MO7e human megakaryocytic leukaemic cells showed no difference between the two formats for any of the three cytokines. Primary human T cells expanded for 9 days in G-Rex® 6M well plates in complete GMP Human T Cell Expansion Media with either 200 IU/mL IL-2 or 10 ng/mL each of IL-7 and IL-15 gave comparable fold expansion, viability near 88 to 90 per cent against 78.5 per cent without cytokines, and similar CD4 and CD8 memory phenotypes.
No manuscripts match your filters.